Poll results: Medical education falters on pain relief

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain.

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain. Of those who responded to ONI’s June poll question-“Do you feel your medical school education in pain relief and opioid pharmacology was adequate?”-71% answered in the negative. Only 14% said that their pain management training was adequate, while 16% said they weren’t sure.

Although the International Association for the Study of Pain has established guidelines for pain management, compliance is spotty, said Kathleen M. Foley, MD, of Memorial Sloan-Kettering Cancer Center, in New York.

The poll was linked to the article, “US cancer patients still plagued by undertreated pain” (June 2008, page 20). To respond to this month’s poll (on page 2), visit www.CancerNetwork.com.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content